The pretreatment lymphocyte-to-monocyte ratio (LMR) to predict treatment efficacy and prognosis in metastatic colorectal cancer treated with the combination of TAS-102 and bevacizumab (TAS-CC3 Study)

被引：0
|
作者：
Matsuda, Akihisa
Yoshida, Yoichiro
Kamiyama, Hirohiko
Kosugi, Chihiro
Yoshida, Hiroshi
Ishibashi, Keiichiro
Ihara, Keisuke
Takahashi, Makoto
Kuramochi, Hidekazu
Fukazawa, Atsuko
Sonoda, Hiromichi
Yoshimatsu, Kazuhiko
Yamaguchi, Satoru
Ishida, Hideyuki
Hasegawa, Suguru
Yamada, Takeshi
Sakamoto, Kazuhiro
Koda, Keiji
机构：
[1] Nippon Med Sch, Dept Gastrointestinal & Hepatobiliary Pancreat Su, Tokyo, Japan
[2] Fukuoka Univ, Fukuoka, Japan
[3] Juntendo Univ, Dept Coloproctol Surg, Sch Med, Bunkyo Ku, Tokyo, Japan
[4] Teikyo Univ, Chiba Med Ctr, Ichihara, Chiba, Japan
[5] Nippon Med Univ, Dept Gastroenterol Surg, Tokyo, Japan
[6] Saitama Med Univ, Saitama, Japan
[7] Dokkyo Univ, Sch Med, Dept Surg Oncol, Mibu, Tochigi, Japan
[8] 3-1-3 Hongo,Bunkyo Ku, Tokyo, Japan
[9] Tokyo Womens Med Univ, Yachiyo Med Ctr, Yachiyoshi Chiba, Japan
[10] Iwata City Hosp, Dept Surg, Shizuoka, Japan
[11] Shiga Univ Med Sci, Dept Surg, Otsu, Shiga, Japan
[12] Saiseikai Kurihashi Hosp, Dept Surg, Kuki, Saitama, Japan
[13] Nippon Med Sch, Dept Digest Surg, Tokyo, Japan
[14] Juntendo Univ, Sch Med, Dept Coloproctol Surg, Tokyo, Japan
[15] Teikyo Univ, Chiba Med Ctr, Ichihara, Chiba, Japan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 38卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
224
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Combination of TAS-102 and bevacizumab as third-line treatment for metastatic colorectal cancer: TAS-CC3 study
    Yoshida, Yoichiro
    Yamada, Takeshi
    Kamiyama, Hirohiko
    Kosugi, Chihiro
    Ishibashi, Keiichiro
    Yoshida, Hiroshi
    Ishida, Hideyuki
    Yamaguchi, Satoru
    Kuramochi, Hidekazu
    Fukazawa, Atsuko
    Sonoda, Hiromichi
    Yoshimatsu, Kazuhiko
    Matsuda, Akihisa
    Hasegawa, Suguru
    Sakamoto, Kazuhiro
    Otsuka, Toshiaki
    Koda, Keiji
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2021, 26 (01) : 111 - 117
  • [2] Combination of TAS-102 and bevacizumab as third-line treatment for metastatic colorectal cancer: TAS-CC3 study
    Yoichiro Yoshida
    Takeshi Yamada
    Hirohiko Kamiyama
    Chihiro Kosugi
    Keiichiro Ishibashi
    Hiroshi Yoshida
    Hideyuki Ishida
    Satoru Yamaguchi
    Hidekazu Kuramochi
    Atsuko Fukazawa
    Hiromichi Sonoda
    Kazuhiko Yoshimatsu
    Akihisa Matsuda
    Suguru Hasegawa
    Kazuhiro Sakamoto
    Toshiaki Otsuka
    Keiji Koda
    International Journal of Clinical Oncology, 2021, 26 : 111 - 117
  • [3] The combination of TAS-102 and bevacizumab as the third line chemotherapy for metastatic colorectal cancer (TAS-CC3 Study)
    Kamiyama, H.
    Yoshida, Y.
    Yoshida, H.
    Kosugi, C.
    Ishibashi, K.
    Ihara, K.
    Takahashi, M.
    Kuramochi, H.
    Fukazawa, A.
    Sonoda, H.
    Yoshimatsu, K.
    Matsuda, A.
    Yamaguchi, S.
    Ishida, H.
    Hasegawa, S.
    Yamada, T.
    Sakamoto, K.
    Koda, K.
    ANNALS OF ONCOLOGY, 2018, 29 : 157 - 157
  • [4] The Pre-treatment Lymphocyte-to-Monocyte Ratio Predicts Efficacy in Metastatic Colorectal Cancer Treated With TAS-102 and Bevacizumab
    Kuramochi, Hidekazu
    Yamada, Takeshi
    Yoshida, Yoichiro
    Matsuda, Akihisa
    Kamiyama, Hirohiko
    Kosugi, Chihiro
    Ishibashi, Keiichiro
    Fukazawa, Atsuko
    Ihara, Keisuke
    Sonoda, Hiromichi
    Yoshimatsu, Kazuhiko
    Yoshida, Hiroshi
    Hasegawa, Suguru
    Sakamoto, Kazuhiro
    Ishida, Hideyuki
    Koda, Keiji
    ANTICANCER RESEARCH, 2021, 41 (06) : 3131 - 3137
  • [5] The combination of TAS-102 and bevacizumab as the third-line chemotherapy for metastatic colorectal cancer (TAS-CC3 Study).
    Kosugi, Chihiro
    Kamiyama, Hirohiko
    Yoshida, Yoichiro
    Yoshida, Hiroshi
    Ishibashi, Keiichiro
    Ihara, Keisuke
    Takahashi, Makoto
    Kuramochi, Hidekazu
    Sonoda, Hiromichi
    Yoshimatsu, Kazuhiko
    Fukazawa, Atsuko
    Matsuda, Akihisa
    Yamaguchi, Satoru
    Ishida, Hideyuki
    Hasegawa, Suguru
    Yamada, Takeshi
    Narushima, Kazuo
    Shuto, Kiyohiko
    Sakamoto, Kazuhiro
    Koda, Keiji
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (04)
  • [6] TAS-102 Monotherapy and Combination Therapy with Bevacizumab for Metastatic Colorectal Cancer
    Liu, Cheng-Jiang
    Hu, Ting
    Shao, Ping
    Chu, Wu-Yang
    Cao, Yu
    Zhang, Feng
    GASTROENTEROLOGY RESEARCH AND PRACTICE, 2021, 2021
  • [7] Pretreatment Neutrophil-to-Lymphocyte Ratio Predicts Survival After TAS-102 Treatment of Patients With Metastatic Colorectal Cancer
    Matsuda, Akihisa
    Yamada, Takeshi
    Matsumoto, Satoshi
    Sakurazawa, Nobuyuki
    Kawano, Youichi
    Shinozuka, Eriko
    Sekiguchi, Kumiko
    Suzuki, Hideyuki
    Yoshida, Hiroshi
    ANTICANCER RESEARCH, 2019, 39 (08) : 4343 - 4350
  • [8] TAS-102 (trifluridine/tipiracil) plus bevacizumab versus TAS-102 alone as salvage treatment options for metastatic colorectal cancer in routine clinical practice
    Shin, Ji Eun
    Lim, Sung Hee
    Lee, Jeeyun
    Lim, Ho Yeong
    Park, Young Suk
    Kim, Seung Tae
    FRONTIERS IN ONCOLOGY, 2024, 14
  • [9] TAS-102 (trifluridine/tipiracil) plus bevacizumab versus TAS-102 alone as salvage treatment options for metastatic colorectal cancer in routine clinical practice
    Shin, J. E.
    Cho, S.
    Lee, J.
    Kim, S. T.
    ANNALS OF ONCOLOGY, 2024, 35 : S1443 - S1443
  • [10] Bevacizumab in Combination with TAS-102 Improves Clinical Outcomes in Patients with Refractory Metastatic Colorectal Cancer: A Retrospective Study
    Fujii, Hironori
    Matsuhashi, Nobuhisa
    Kitahora, Mika
    Takahashi, Takao
    Hirose, Chiemi
    Iihara, Hirotoshi
    Yamada, Yunami
    Watanabe, Daichi
    Ishihara, Takuma
    Suzuki, Akio
    Yoshida, Kazuhiro
    ONCOLOGIST, 2020, 25 (03): : E469 - E476
12345